IGM Biosciences, Inc. (IGMS)

7.39 -0.74 (-9.11%) As of 02:06PM EDT. Market open.

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
https://igmbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 224

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Fred M. Schwarzer J.D.	CEO, President & Director	977.66k	N/A	1953
Dr. Bruce A. Keyt Ph.D.	Chief Scientific Officer	692.95k	N/A	1954
Dr. Chris H. Takimoto FACP, M.D., Ph.D.	Chief Medical Officer	684.95k	N/A	1959
Mr. Misbah Tahir	Chief Financial Officer	957.6k	N/A	1976
Mr. TS Harigopal	Senior Vice President of Group Operations	N/A	N/A	N/A
Mr. Steven Weber	Senior VP, Corporate Controller & Principal Accounting Officer	N/A	N/A	1976
Mr. Paul C. Graffagnino	Senior Vice President of Legal Affairs	N/A	N/A	N/A
Ms. Suzette Tauber	Chief Human Resources Officer	N/A	N/A	1964
Dr. Angus M. Sinclair Ph.D.	Senior Vice President of Immuno-Oncology	N/A	N/A	N/A
Dr. Lisa L. Decker Ph.D.	Chief Business Officer	528.18k	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Corporate governance

IGM Biosciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.